Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration.

2.50
Hdl Handle:
http://hdl.handle.net/10541/80223
Title:
Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration.
Authors:
Booton, Richard ( 0000-0003-4512-2899 ) ; Thatcher, Nick
Abstract:
Platinum-based combination and single-agent chemotherapy have become accepted as treatments for locally advanced and metastatic nonsmall cell lung cancer as a consequence of improved survival, quality of life, and symptom control compared with best supportive care. However, it is clear that a therapeutic plateau has been reached with current combinations requiring a re-evaluation of strategies to improve clinical outcomes. Dose intensification may offer one way in which to achieve better results, as may extension of the duration of treatment. The evidence suggests that dose intensification is a useful tool, and that its use in combination with markers of treatment duration and cumulative dose may help to maximize results from current active drug combinations.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom.
Citation:
Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration. 2002, 14 (2):191-8 Curr Opin Oncol
Journal:
Current Opinion in Oncology
Issue Date:
Mar-2002
URI:
http://hdl.handle.net/10541/80223
PubMed ID:
11880710
Type:
Article
Language:
en
ISSN:
1040-8746
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorBooton, Richard-
dc.contributor.authorThatcher, Nick-
dc.date.accessioned2009-09-08T09:19:00Z-
dc.date.available2009-09-08T09:19:00Z-
dc.date.issued2002-03-
dc.identifier.citationChemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration. 2002, 14 (2):191-8 Curr Opin Oncolen
dc.identifier.issn1040-8746-
dc.identifier.pmid11880710-
dc.identifier.urihttp://hdl.handle.net/10541/80223-
dc.description.abstractPlatinum-based combination and single-agent chemotherapy have become accepted as treatments for locally advanced and metastatic nonsmall cell lung cancer as a consequence of improved survival, quality of life, and symptom control compared with best supportive care. However, it is clear that a therapeutic plateau has been reached with current combinations requiring a re-evaluation of strategies to improve clinical outcomes. Dose intensification may offer one way in which to achieve better results, as may extension of the duration of treatment. The evidence suggests that dose intensification is a useful tool, and that its use in combination with markers of treatment duration and cumulative dose may help to maximize results from current active drug combinations.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Agents-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshTime Factors-
dc.titleChemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom.en
dc.identifier.journalCurrent Opinion in Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.